Role of Endolysosomes in Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Coronavirus Disease 2019 Pathogenesis: Implications for Potential Treatments

Nabab Khan, Xuesong Chen and Jonathan D. Geiger*

Department of Biomedical Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND, United States

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is an enveloped, single-stranded RNA virus. Humans infected with SARS-CoV-2 develop a disease known as coronavirus disease 2019 (COVID-19) with symptoms and consequences including acute respiratory distress syndrome (ARDS), cardiovascular disorders, and death. SARS-CoV-2 appears to infect cells by first binding viral spike proteins with host protein angiotensin-converting enzyme 2 (ACE2) receptors; the virus is endocytosed following priming by transmembrane protease serine 2 (TMPRSS2). The process of virus entry into endosomes and its release from endolysosomes are key features of enveloped viruses. Thus, it is important to focus attention on the role of endolysosomes in SARS-CoV-2 infection. Indeed, coronaviruses are now known to hijack endocytic machinery to enter cells such that they can deliver their genome at replication sites without initiating host detection and immunological responses. Hence, endolysosomes might be good targets for developing therapeutic strategies against coronaviruses. Here, we focus attention on the involvement of endolysosomes in SARS-CoV-2 infection and COVID-19 pathogenesis. Further, we explore endolysosome-based therapeutic strategies to restrict SARS-CoV-2 infection and COVID-19 pathogenesis.

Keywords: endolysosome, endocytosis, two pore channel

INTRODUCTION

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) that causes the pandemic disease known as coronavirus disease 2019 (COVID-19) (Contini et al., 2020; Gudbjartsson et al., 2020) is an enveloped virus that contains a large single-stranded RNA genome (Chen et al., 2020; Huang et al., 2020; Lu et al., 2020; Ren et al., 2020). SARS-CoV-2 belongs to the same beta-coronavirus family as does SARS-CoV that caused the SARS outbreak in China in 2002 (Cherry, 2004) and Middle East respiratory syndrome coronavirus (MERS-CoV) that caused the MERS outbreak in Saudi Arabia in 2012 (Zaki et al., 2012; Li and Du, 2019). Similar to other enveloped coronaviruses, SARS-CoV-2 enters host cells by endocytosis and uses host cell machinery for replication.
Spiked glycoproteins on the outer surface of coronaviruses are recognized by and bind to cell surface receptors such as angiotensin-converting enzyme 2 (ACE2) (Huang et al., 2006; Hoffmann et al., 2020b; Shang et al., 2020b) as well as possibly other co-receptors (Raj et al., 2013). Following binding, receptor-bound virus is endocytosed whereupon the viral genome is delivered into the cytoplasm; endocytosis mechanisms are pH-dependent and -independent (Dimitrov, 2004; White and Whittaker, 2016). Viruses that co-opt pH-independent mechanisms, an example of which is HIV-1, fuse with cell surface membranes and use endocytic pathways to achieve infection (White and Whittaker, 2016). Viruses that enter cells by pH-dependent mechanisms fuse with endosome membranes and use host factors associated with endosomes to enable viral entry into cells (Yang et al., 2004; White and Whittaker, 2016).

Coronaviruses use endolysosome-associated cathepsin B and L proteases under acidic conditions and are considered to be late penetrating viruses (late-entry kinetic mechanism) (Follis et al., 2006; Bosch et al., 2008; Millet and Whittaker, 2014; Coutard et al., 2020; Hoffmann et al., 2020a; Hoffmann et al., 2020b; Pranesh et al., 2020). Following entry, coronaviruses are released into the cytosol from endolysosomes or are targeted for degradation in lysosomes. In addition, some coronaviruses including SARS-CoV-2 can escape endolysosomes and replicate in autophagosome-like structures in the cytosol (Maier and Britton, 2012; Chen et al., 2014; Gassen et al., 2019; Gassen et al., 2020). Accordingly, it is important to focus attention on the role of endolysosomes in early stages of interactions between the virus and host cells as well as COVID-19 pathogenesis.

THE ACIDIC NATURE OF ENDOLYSOSOMES

Endosomes are formed from plasma membrane invaginations; a process known as endocytosis. These acidic organelles are categorized further as early, late and recycling endosomes; all with different compositions and hydrogen ion (H+) content (Luzio et al., 2007; Huotari and Helenius, 2011; Gautreau et al., 2014). Rab4 and Rab5 are important components of early endosomes and function optimally at a pH range of 5.5–6.0. Early endosomes participate in signaling between the extracellular and intracellular environments (Pálfy et al., 2012; Villasenor et al., 2016); they can recycle to plasma membranes thereby returning endocytosed constituents back to the cell surface (McCaffrey et al., 2001; Grant and Donaldson, 2009; Hsu and Prekeris, 2010). Alternatively, early endosomes can mature and transform into late endosomes (Bright et al., 2005; Luzio et al., 2007); these are differentiated from early endosomes by the expression of Rab7 and have an optimal pH range of 5.0–5.5 (Vanladingham and Ceresa, 2009; Guerra and Bucci, 2016). Late endosomes can also recycle to plasma membranes (Guerra and Bucci, 2016), can produce multi-vesicular bodies from which extracellular vesicles (exosomes) originate, or can fuse with lysosomes (Piper and Luzio, 2001; Traub, 2010). The fusion of late endosomes with lysosomes generates endolysosomes under more acidic conditions ranging from pH 4.5–5.0 (Figure 1) (Mullock et al., 1998; Luzio et al., 2007; Luzio et al., 2010). The tight range of H+ concentrations in these organelles controls enzymatic activities as well as fusions between autolysosomes and lysosomes, and lysosomes and endosomes; pH also affects autophagy and other important cellular processes (Luzio et al., 2007; Luzio et al., 2010; Nakamura and Yoshimori, 2017). Vacular-ATPase (v-ATPase) activity largely regulates the acidic nature of endolysosomes and does so by controlling the flux of cations and anions via hydrolysis of free ATP that drives protons against their electrochemical gradient into the lumen of endolysosomes (Mindell, 2012; Halcrow et al., 2019a; Khan et al., 2019a).

Endolysosomes are involved in a wide range of cellular processes including membrane trafficking, catabolism of extracellular and intracellular components, immune responses and antigen presentation, cell secretions, and cell life and death (Eskelinen and Saftig, 2009; Munz, 2012; Repnik et al., 2013; Bright et al., 2016; Truschel et al., 2018; Khan et al., 2019a; Afgah et al., 2020). These acidic organelles have also been implicated in various pathological conditions; structural and functional changes have been reported in various neurodegenerative disorders as well as in cancer (Repnik et al., 2013; Bright et al., 2016; Davis, 2018; Halcrow et al., 2019a; Khan et al.,...
and Pöhlmann, 2004; Belouzard et al., 2012; Shang et al., 2020a). Because endolysosome pH regulates structural and functional features of endolysosomes, the involvement of v-ATPase in disease pathogenesis has received much attention and the v-ATPase complex has been targeted for therapeutic reasons. Indeed, inhibitors of v-ATPase and other strategies to keep endolysosomes from de-acidifying has shown benefit against diverse pathological conditions including different types of cancer (Whitton et al., 2018; Halcrow et al., 2019a; Halcrow et al., 2019b), neurological complications (Colacurcio and Nixon, 2016), and infectious diseases (Luzio et al., 2007).

CORONAVIRUS ENTRY INTO AND ESCAPE FROM ENDOLYSOSOMES:

Coronaviruses once endocytosed can avoid immune surveillance detection and degradation; thus enhancing infection (Hofmann and Pöhlmann, 2004; Belouzard et al., 2012; Shang et al., 2020a; Letko et al., 2020; Stower, 2020). SARS-CoV and MERS-CoV bind principally to dipeptidyl peptidase 4 while SARS-CoV-2 appears to bind mainly to ACE2; regardless, coronavirus spike proteins are activated by the host proteases TMPRSS2 or cathepsin B/L (Bosch et al., 2008; Shirato et al., 2013; Zhou et al., 2015; Hoffmann et al., 2020b; Pranesh et al., 2020). In addition, SARS-CoV-2 and MERS-CoV are activated by furin and this enhances viral entry especially in cells with lower expression levels of lysosomal cathepsin (Follis et al., 2006; Millet and Whittaker, 2014; Coutard et al., 2020; Hoffmann et al., 2020a).

Coronaviruses enter host cells by pH-dependent endocytosis (Yang et al., 2004; Burkard et al., 2014; Hoffmann et al., 2020b) and the acidic environment of endolysosomes is regulated not only by v-ATPase (Mindell, 2012), but also by Na⁺/K⁺-ATPase (Gain et al., 1989), mucolipin (TRPML1) channels (Li M. et al., 2017), big potassium channels (BK and MaxiK) (Khan et al., 2019b), Niemann-Pick type C (NPC1) (Wheeler et al., 2019a; Wheeler et al., 2019b; Höglinger et al., 2019; Lim et al., 2019), and two-pore channels (TPCs) (Marchant and Patel, 2015; Grimm et al., 2017; Khan et al., 2020). To date, TPCs and NPC1 have both been implicated in coronavirus infectivity.

TPCs are present in two forms; TPC1 and TPC2. TPC1s are mainly localized on early endosomes while TPC2s are mainly found on late endosomes/lysosomes (Brailoiu et al., 2009; Pitt et al., 2010; Zakon, 2012). Both subtypes of TPCs can help orchestrate interactions between endolysosomes and such viruses as Ebola (Sakurai et al., 2015), MERS-CoV (Gunaratne et al., 2018), and SARS-CoV-2 (Ou et al., 2020); TPCs regulate the trafficking of virus to late-endosomes/lysosomes following entry into cells. Not surprisingly then, TPC inhibitors can block entry of SARS-CoV-2 into cells and restrict the release of viral RNA into the cytosol (Figure 2) (Ou et al., 2020). TPCs are also involved in chloroquine-mediated endolysosome leakage and facilitated the release of HIV-1 Tat protein from endolysosomes thus enabling activation of HIV-1 LTR transactivation in the nucleus (Khan et al., 2020). Therefore, TPCs appear to promote virus entry and facilitate the release and transport of viral RNA to replication sites by inducing endolysosome permeability and depolarization.

NPC1 appears to also play a role in virus entry and infectivity. SARS-CoV enters into early endosomes, traffics to NPC1-positive late endosomes and lysosomes, and accesses highly active cathepsin L protease that triggers fusion mechanisms (Figure 2) (Shah et al., 2010; Zheng et al., 2018). MERS-CoV, Ebola, and SARS-CoV-2 use similar mechanisms to enter into host cells (Mingo et al., 2015; Zhou et al., 2016; Ballout et al., 2020).

AUTOPHAGY AND CORONAVIRUS REPLICATION

Autophagy is a process by which extracellular and intracellular macromolecules are engulfed in and degraded by autophagolysosomes; structures formed by fusion of lysosomes with autophagosomes (Eskelinen and Saftig, 2009; Kenney and Benarroch, 2015; Yim and Mizushima, 2020). Autophagy is regulated by diverse proteins including autophagy-related genes (ATGs), Beclin, ubiquitin-binding protein (p62), 5′-adenosine monophosphate-activated protein kinase, serine/threonine kinase 1 (Akt), and S-phase kinase-associated protein 2 (Skp2) (He and Klionsky, 2009; Badadani, 2012).

The process of autophagy degrades invading viruses, enhances antigen processing and presentation, and induces adaptive immune responses (Lee and Kim, 2007; Delgado et al., 2009; Richetta and Faure, 2013; Choi et al., 2018a). For example, toll-like receptors are pattern recognition receptors that sense viral RNA and DNA in endolysosomes, induce type I-interferon responses, and following induction of autophagy antiviral immune responses are decreased and invading viruses are degraded (Lee and Kim, 2007; Dalpke and Helm, 2012; Choi et al., 2018a). Autophagy has antiviral effects independent of the degradation process; interferon-γ can suppress replication of norovirus (Hwang et al., 2012; Baldridge et al., 2016; Biering et al., 2017). Additionally, viruses can modulate, escape, and inhibit autophagy at multiple steps to survive and replicate in host cells (Pattingre et al., 2005; Kyei et al., 2009; Chaumorcel et al., 2012).

Autophagy plays a role in viral infections including those caused by coronaviruses (Prentice et al., 2004a; Killian, 2012; Maier and Britton, 2012). Mouse hepatitis virus (MHV) has been used as a model for coronavirus infections (Prentice et al., 2004a); the replication complex of MHV generates double-membrane vesicles (DMVs) resembling autophagosomes (Snijder et al., 2006; Clementz et al., 2008; Gadlage et al., 2010) within which the autophagy markers LC3 and ATG12 colocalize (Prentice et al., 2004a). MHV replication is impaired when the autophagy marker ATG5 is knocked down (Prentice et al., 2004a). Replication proteins of SARS-CoV colocalize with LC3 and autophagy appears to play an important role in SARS-CoV replication (Prentice et al., 2004b). In contrast, SARS-CoV and MHV replication was not impaired when ATG5 and ATG7 were knocked down (Zhao et al., 2007; Reggiori et al., 2010; Schneider et al., 2012). The MERS-CoV and SARS-CoV associated protein, membrane-associated papain-like proteases, suppressed autophagy flux by blocking the fusion of lysosomes and autophagosomes (Chen X. et al., 2014; Gassen et al., 2019).
Similarly, SARS-CoV-2 suppresses autophagy by modulating multiple autophagy regulatory factors (Gassen et al., 2020), by blocking the degradation of viral factors, and by increasing the formation of DMVs to promote virus replication. Induction of autophagy reduced the replication and infectivity of MERS-CoV (Gassen et al., 2019; Carmona-Gutierrez et al., 2020) and SARS-CoV-2 (Maier and Britton, 2012; Gassen et al., 2020).

**ENDOLYSOSOME-BASED THERAPEUTIC STRATEGIES TO INHIBIT SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 INFECTION**

Because endolysosomes influence coronavirus infections, these organelles might be targeted against SARS-CoV-2 infection and COVID-19 pathogenesis. Given the urgency of need and the tremendous costs involved in developing new drugs, a good approach to therapeutic drug development is the repurposing of drugs known to accumulate in and affect the function of endolysosomes. The diprotic weak base drugs chloroquine (CQ) and hydroxychloroquine (HCQ), that de-acidify endolysosomes, have shown effectiveness in controlling SARS-CoV-2 infection in *in vitro* studies, however the effectiveness of CQ/HCQ against COVID-19 has not been established for COVID-19 patients (Liu et al., 2020; Wang et al., 2020; Yao et al., 2020). Endolysosome de-acidification can restrict replication of SARS-CoV-2 because acidic conditions are necessary for SARS-CoV-2 to enter into and be released from host cells. In the context of SARS-CoV-2 infection, CQ and HCQ have been used in combination with azithromycin (Andreani et al., 2020; Carlucci et al., 2020); a weak base antibiotic known to accumulate in endolysosomes (Kong...
et al., 2017; Choi et al., 2018b; Andreani et al., 2020). Of course, CQ and HCQ have other pharmacological actions, but the involvement of endolysosomes de-acidification in SARS-CoV-2 infection is supported by findings that other endolysosome de-acidification drugs; ammonium chloride, baflomycin A1 and monensin all block coronavirus infections at the entry-level (Hoffmann et al., 2020b; Pranesh et al., 2020; Yang and Shen, 2020).

However, de-acidification may have other unintended consequences that might result in increased viral levels. Acidic conditions in endolysosomes are necessary for TLR-induced type-I interferon-mediated antiviral immune responses and antigen presentation (Dalpke and Helm, 2012; Munz, 2012; Choi et al., 2018a; Viret et al., 2020). Acidic endolysosomes are also important for autophagy, which is important for initiating innate immune responses and the degradation of viruses (Dalpke and Helm, 2012; Choi et al., 2018a).

Accordingly, de-acidification of endolysosomes might hamper autophagy-mediated antiviral responses (Kužnik et al., 2011) by deactivating RNA sensors (Belizaire and Unanue, 2009; Kužnik et al., 2011; Kazi et al., 2013; Hussman, 2020; Offerhaus et al., 2020; Schrezenmeier and Dörner, 2020). Therefore, improving innate immune responses using synthetic RNAs, oligonucleotides, or small agonists of TLRs as well as type-I interferon treatment might improve clinical responses to CQ and HCQ (Dalpke and Helm, 2012; Freund et al., 2019; Hussman, 2020; Lee and Shin, 2020).

**INHIBITION OF CORONAVIRUSES AT THE ENTRY LEVEL**

The spike protein of SARS-CoV-2 is necessary for viral entry into cells governed by receptor-mediated endocytosis (Hofmann and Pöhlmann, 2004; De Clercq, 2006; Burkard et al., 2014; Burkard et al., 2014; Zheng et al., 2018; Jiang et al., 2020; Ou et al., 2020; Shang et al., 2020a; Tay et al., 2020). SARS-CoV-2 spike is a trimer with three receptor-binding domains (RBDs) of S1 heads on top of a trimeric S2 stalk (Gui et al., 2017; Shang et al., 2020a; Walls et al., 2020). Following proteolytic cleavage, the RBD of S1 conformationally switches from a laid-down position to a standing-up position in order to facilitate fusion with cell membranes (Hofmann and Pöhlmann, 2004; Gui et al., 2017; Yuan et al., 2017; the laid-down position has a significantly higher binding capacity (Walls et al., 2020; Wrapp et al., 2020) and escapes host immune surveillance. These features of the spike protein might make development of vaccines and antibody-based therapies more challenging (Figure 2) (Rossmann, 1989; Sui et al., 2014; VanBlargan et al., 2016; Gui et al., 2017; Chu et al., 2020; Xia et al., 2020). Never-the-less, huge efforts are on-going to develop vaccines and antibody-based therapies based on the structural and binding properties of RBDs (Jiang et al., 2005; Du et al., 2014; Shang et al., 2020b; Tai et al., 2020).

Additional sites for intervention against viral infection include the spike S2 stalk that contains HR1 and HR2 hydrophobic regions; stable six-helix-bundle (6-HB) structures that fuse the virus with the host cell membrane (Figure 2) (Bosch et al., 2003; Bosch et al., 2004; Aydin et al., 2014; Wang et al., 2019). These mechanisms might represent sites for intervention against viral replication because targeting these hydrophobic regions has been shown to restrict infection of HIV-1 (Kong et al., 2016; Yuan et al., 2019), SARS-CoV-2, and other coronaviruses (Bosch et al., 2004; Xia et al., 2019a; Xia et al., 2019b; Wang et al., 2019; Xia et al., 2020).

Post-fusion with plasma membranes, many viruses enter cells by endocytosis and clathrin-mediated endocytosis (Inoue et al., 2007; Wang et al., 2008). Therefore it is not surprising that the anti-schizophrenia drug chlorpromazine (Ban, 2007) that inhibits clathrin-mediated endocytosis inhibits infection by the coronaviruses MHV (Pu and Zhang, 2008), MERS-CoV (Burkard et al., 2014), and SARS-CoV (Inoue et al., 2007; Wang et al., 2008). Similarly, Na⁺/K⁺-ATPase pump-based inhibitors bufalin and ouabain restricted MERS-CoV infection (Burkard et al., 2014; Burkard et al., 2015; Amarelle and Lecuona, 2018) by inhibiting clathrin-mediated endocytosis (Ko et al., 2020). An additional FDA approved drug that might find use against COVID-19 is camostat mesylate that is used for the treatment of pancreatitis (Ramsey et al., 2019); it inhibited serine proteases and restricted MERS-CoV, SARS-CoV, and SARS-CoV-2 infections by inhibiting TMPRSS2 activity (Figure 2) (Shirato et al., 2013; Bojkova et al., 2020; Hoffmann et al., 2020b). Also, the cathepsin L inhibitors Z-FY (t-Bu)-DMK, K1777, and teicoplanin blocked the entry of SARS-CoV and MERS-CoV (Huang et al., 2006; Adedeji et al., 2013; Zhou et al., 2016; Baron et al., 2020). Accordingly, the above named agents might find use against SARS-CoV-2 infection (Figure 2) and the pathogenesis of COVID-19.

**EFFECTS OF ENDOlysosOME pH ON CORONAVIRUS INFECTION**

The coronavirus spike protein is activated under acidic conditions by the endolysosome proteases TMPRSS2 and cathepsins B, L; conditions that promote fusion with host cell membranes and entrance into cells (Hoffmann et al., 2020b). Consistent with this, de-acidification of endolysosomes by CQ, baflomycin A1, and ammonium chloride have all been shown to deactivate TMPRSS2 and cathepsin B, L as well as suppress coronavirus infection (Figure 2) (Simmons et al., 2004; Vincent et al., 2005; Wang et al., 2008; Shirato et al., 2013; Al-Bari, 2017; Gao et al., 2020; Hoffmann et al., 2020b). Although mentioned earlier, it is important to consider more specifically the involvement of endolysosome-resident ion channels and proteins that regulate endolysosome pH including TPCs, NPC1, and v-ATPase.

TPCs are calcium- and sodium-permeable channels that regulate cell membrane trafficking and endolysosome pH (Wang et al., 2012; Lagostena et al., 2017; Khan et al., 2020). Because of the involvement of TPCs in the regulation of endolysosome pH it is not surprising that TPC activation increased the entry and trafficking of SARS-CoV-2 (Ou et al., 2020), MERS-CoV (Gunaratne et al., 2018) and Ebola.
Niemann-Pick disease type C1 (NPC1) is an endolysosome-resident protein (Higgins et al., 1999) that regulates trafficking of late endosomes and lysosomes (Ko et al., 2001; Zhang et al., 2001; Ganley and Pfeffer, 2006; Sztolsztener et al., 2012), membrane trafficking of essential cellular factors such as cholesterol and sphingolipids (Chen et al., 2005; Infante et al., 2008; Kwon et al., 2009; Lange et al., 2012; Högländer et al., 2019), and regulation of endolysosome pH and calcium (Elrick et al., 2012; Liu and Lieberman, 2019; Wheeler et al., 2019a). Impaired NPC1 is an underlying cause of Niemann-Pick disease; a lysosome storage disease (Lloyd-Evans et al., 2008; Rhoden et al., 2018; Schloer et al., 2019a). CQ, Baf A1 and ammonium chloride all cause de-acidification and deactivation of proteases in endolysosomes as well as inhibit coronavirus infections (Vincent et al., 2005; Gao et al., 2020; Hoffmann et al., 2020b). The SARS-CoV 3CLPro protease de-acidifies endolysosomes by direct interaction with the G1 subunit of v-ATPase (Lin et al., 2005) and blocks degradation of viral factors thereby enhancing virus replication. Endolysosome acidification may also restrict coronavirus infections by blocking the escape of viral RNA to the cytosol and promoting viral degradation in lysosomes (Carmona-Gutierrez et al., 2020; Gassen et al., 2020; Yang and Shen, 2020). A number of natural compounds acidify endolysosomes and might be tested for their ability to enhance coronavirus degradation; these include spermidine and spermine (Gassen et al., 2020), baicalein (Zhu et al., 2020), vitamin D3 (Hu et al., 2019; Daneshkhhah et al., 2020), 17-beta-estradiol (Lipovka and Konhilas, 2014; Xiang et al., 2019; Khan, 2020; Suba, 2020), ketone bodies (Hui et al., 2012; Camberos-Luna et al., 2016), trehalose (Sharma et al., 2020), wogonin (Li et al., 2016), apigenin (Zhang X. et al., 2019), and butein (Ansari et al., 2018) (Figure 2).

CONCLUSION

The high fatality rate of COVID-19 especially among people with pre-existing co-morbidities and rapidly increasing case numbers of SARS-CoV-2 infections has created a huge global need for effective therapeutic interventions against COVID-19. Because of the urgent need for therapeutics, re-purposing already approved pharmaceuticals might be the quickest available strategy. SARS-CoV-2 enters into endolysosomes where it can escape detection by immune surveillance and from there can traffic to the cytosol where it can propagate. Endolysosomes generally and endolysosome pH more specifically may represent important targets against SARS-CoV-2 replication and COVID-19 pathogenicity, and several compounds and drugs are available that may be repurposed for immediate testing. Reviewed above were several potential targets to block SARS-CoV-2 infection including endocytosis following binding of the spike protein with its receptor (ACE2), RNA replication and transcription, translation and proteolytic processing of viral proteins, virion assembly, and release from infected cells (Guy et al., 2020; Poduri et al., 2020); all targets involving the endolysosome
system. In considering approaches against SARS-CoV-2 infection and COVID-19 pathogenesis, the involvement of endolysosomes should be considered.

**DATA AVAILABILITY STATEMENT**

All datasets presented in this study are included in the article/supplementary material.

**REFERENCES**

Adejala, O. A., Severson, W., Jonsson, C., Singh, K., Weiss, S. R., and Sarafianos, S. G. (2013). Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. *J. Virol.*, 87, 8017–8028. doi:10.1128/jvi.00998-13

Afghah, Z., Chen, X., and Geiger, J. D. (2020). Role of endolysosomes and interorganellar signaling in brain disease. *Neurobiol. Dis.*, 134, 104670. doi:10.1016/j.nbd.2019.104670

Al-Bari, M. A. A. (2017). Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. *Pharmacol. Res. Perspect.*, 5, e00293. doi:10.1002/prp2.293

Amarelle, L., and Lecuona, E. (2018). The antiviral effects of Na,K-ATPase inhibition: a minireview. *Int. J. Mol. Sci.*, 19, 2154. doi:10.3390/ijms19082154

Andreati, J., Le Bideau, M., Duflot, I., Jardot, P., Rolland, C., Boxberger, M., et al. (2020). *In vitro* testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. *Microb. Pathog.*, 145, 104228. doi:10.1016/j.micpath.2020.104228

Ansari, M. Y., Ahmad, N., and Haqqi, T. M. (2018). Butein activates autophagy through AMPK/TSC2/ULK1/mTOR pathway to inhibit IL-6 expression in IL-1β stimulated human chondrocytes. *Cell. Physiol. Biochem.*, 49, 932–946. doi:10.1159/000493225

Aydin, H., Al-Khooly, D., and Lee, J. E. (2014). Influence of hydrophobic and electrostatic residues on SARS-coronavirus S2 protein stability: insights into mechanisms of general viral fusion and inhibitor design. *Protein Sci.*, 23, 603–617. doi:10.1002/pro.2442

Badalani, M. (2012). Autophagy mechanism, regulation, functions, and disorders. *ISRN Cell Biol.*, 2012, 927064. doi:10.5402/2012/927064

Bai, Y., Peng, W., Yang, C., Zou, W., Liu, M., Wu, H., et al. (2020). Pharmacokinetics and metabolism of naringin and active metabolite naringenin in rats, dogs, humans, and the differences between species. *Front. Pharmacol.*, 11, 364. doi:10.3389/fphar.2020.00364

Bailly, C. (2019). Cepharanthine: an update of its mode of action, pharmacological properties and medical applications. *Phytochemistry*, 62, 152956. doi:10.1016/j.phytochem.2019.125956

Baldridge, M. T., Turula, H., and Wobus, C. E. (2016). Norovirus regulation by host system. *J. Virol.*, 87, 8017–8028. doi:10.1128/jvi.00998-13

AUTHOR CONTRIBUTIONS

All authors contributed equally to the manuscript.

**FUNDING**

P30GM100329, U54GM115458, R01MH100972, R01MH105329, R01MH119000, 2R01NS065957, and 2R01DA032444.

Benkerrou, D., Minicozzi, V., Gradogna, A., Milenkovic, S., Bodrenko, I. V., Festa, M., et al. (2019). A perspective on the modulation of plant and animal two pore channels (TPCs) by the flavonoid naringenin. *Biophys. Chem.*, 25, 106246. doi:10.1016/j.bpc.2019.106246

Biering, S. B., Choi, J., Halstrom, R. A., Brown, H. M., Beatty, W. L., Lee, S., et al. (2017). Viral replication complexes are targeted by LC3-guided interferon-inducible GTPases. *Cell Host Microbe*, 22, 74–85. doi:10.1016/j.chom.2017.06.005

Bojkova, D., McGreigh, J. E., McLaughlin, K.-M., Masterson, S. G., Widera, M., Krathling, V., et al. (2020). SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles. *bioRxiv* doi:10.1101/2020.04.03.024257

Bosch, B. J., Bartelink, W., and Rottier, P. J. M. (2008). Cathespin I functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide. *J. Virol.*, 82, 8887–8890. doi:10.1128/jvi.00415-08

Bosch, B. J., Martina, B. E. E., van der Zee, R., Lepaut, J., Hajemaja, B. J., Versluis, C., et al. (2004). Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. *Proc. Natl. Acad. Sci. U.S.A.*, 101, 8455–8460. doi:10.1073/pnas.0400789101

Bosch, B. J., van der Zee, R., de Haan, C. A. M., and Rottier, P. J. M. (2003). The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. *J. Virol.*, 77, 8801–8811. doi:10.1128/jvi.77.21.8801–8811.2003

Bright, N. A., Davis, L. J., and Luzio, J. P. (2016). Endolysosomes are the principal intracellular sites of acid hydrolase activity. *Curr. Biol.*, 26, 2233–2245. doi:10.1016/j.cub.2016.06.046

Bright, N. A., Gratian, M. J., and Luzio, J. P. (2005). Endocytic delivery to lysosomes mediated by concurrent fusion and kissing events in living cells. *Curr. Biol.*, 15, 360–365. doi:10.1016/j.cub.2005.01.049

Burkard, C., Verheij, M. H., Haagmans, B. L., van Kuppeveld, F. J., Rottier, P. J. M., Bosch, B. J., et al. (2015). ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells. *J. Virol.*, 89, 4434–4448. doi:10.1128/jvi.03274-14

Burkard, C., Verheije, M. H., Wicht, O., van Kasteren, S. I., van Kuppeveld, F. J., Haagmans, B. L., et al. (2014). Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. *PLoS Pathog.*, 10, e1004502. doi:10.1371/journal.ppat.1004502

Cain, C. C., Sipe, D. M., and Murphy, R. F. (1989). Regulation of endocytic pH by host and microbe. *Trends Mol. Med.*, 22, 1047–1059. doi:10.1016/j.molmed.2016.10.003

Ballout, R. A., Srividov, D., Bukrinsky, M. I., and Remaley, A. T. (2020). The lysosome: a potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications. *FASEB J.*, 34, 7253–7264. doi:10.1096/fj.202000654R

Baron, S. A., Devaux, C., Colson, P., Raoul, D., and Rolain, J.-M. (2020). Teicoplanin: an alternative drug for the treatment of COVID-19? *Int. J. Antimicrob. Agents*, 55, 105944. doi:10.1016/j.ijantimicag.2020.105944

Belizaire, R., and Unanue, E. R. (2009). Targeting proteins to distinct subcellular compartments reveals unique requirements for MHc class I and II presentation. *Proc. Natl. Acad. Sci. U.S.A.*, 106, 17463–17468. doi:10.1073/pnas.0908258106

Belouzard, S., Millet, J. K., Licitra, B. N., and Whitlacker, G. R. (2012). Mechanisms of coronavirus cell entry mediated by the viral spike protein. *Viruses*, 4, 1011–1033. doi:10.3390/v40401101

Carlucci, P., Ahuja, T., Petrilli, C. M., Rajagopalan, H., Jones, S., and Rahimian, J. (2020). Hydroxycarbochlorine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients. *medRxiv* doi:10.1099/mmm.0.001250

Caires, K. L., and Burkard, C. (2020). Role of endolysosomes in SARS-CoV-2 Infection. *Frontiers in Pharmacology*, 11, 595888. doi:10.3389/fphar.2020.595888
Gunaratne, G., Yang, Y., Li, F., Walseth, T., and Marchant, J. (2018). NAADP-Gui, M., Song, W., Zhou, H., Xu, J., Chen, S., Xiang, Y., et al. (2017). Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Res. 27, 119–129. doi:10.1038/cr.2016.152

Gunaratne, G., Yang, Y., Li, F., Walseth, T., and Marchant, J. (2018). NAADP-dependent Ca^{2+} signaling regulates Middle East respiratory syndrome coronavirus pseudovirus translocation through the endolysosomal system. Cell Calcium 75, 30–34. doi:10.1016/j.ceca.2018.08.003

Guy, R. K., DiPaola, R. S., Romanelli, F., and Dutch, R. E. (2020). Rapid repurposing of drugs for COVID-19. Science 368, 829–830. doi:10.1126/science.abb9332

Infante, R. E., Wang, M. L., Radhakrishnan, A., Kwon, H. J., Brown, M. S., and Goldstein, J. I. (2008). NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes. Proc. Natl. Acad. Sci. U. S. A. 105, 15287–15292. doi:10.1073/pnas.0807328105

Höglinger, D., Burgoyne, T., Sanchez-Heras, E., Hartwig, P., Colaco, A., Newton, J., et al. (2019). NPC1 regulates ER contacts with endocytic organelles to mediate cholesterol egress. Nat. Commun. 10, 4276. doi:10.1038/s41467-019-12152-2

Halcrow, P., Datta, G., Ohm, J. E., Soliman, M. L., Chen, X., and Geiger, J. D. (2019a) Role of endolysosomes and pH in the pathogenesis and treatment of glioblastoma. Cancer Res. 2. doi:10.1158/canres.2019.106404

Halcrow, P., Khan, N., Datta, G., Ohm, J. E., Chen, X., and Geiger, J. D. (2019b) Importance of measuring endolysosome, cytosolic, and extracellular pH in understanding the pathogenesis of and possible treatments for glioblastoma multiforme. Cancer Res. 2. doi:10.1102/canres.2.1193

He, C., and Klionsky, D. J. (2009). Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet. 43, 67–93. doi:10.1146/annurev-genet-102808-114910

Herbert, A. S., Davidson, C., Kuehne, A. I., Bakken, R., Braigen, S. Z., Gunn, K. E., Higgins, M. E., Davies, J. P., Chen, F. W., and Ioannou, Y. A. (1999). Niemann-Pick disease: potential points of therapeutic intervention. Front. Pharmacol. 11, 1169. doi:10.3389/fphar.2020.01169

Hwang, S., Maloney, N. S., Brunisma, M. W., Goel, G., Duan, E., Zhang, L., et al. (2012). Nondegradative role of atg5-atg12/Atg16L1 autophagy protein complex in antiviral activity of interferon gamma. Cell Host Microbe 11, 397–409. doi:10.1016/j.chom.2012.03.002

Inoue, Y., Tanaka, N., Tanaka, Y., Inoue, S., Morita, K., Zhuang, M., et al. (2007). Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted. J. Virol. 81, 8722–8729. doi:10.1128/jvi.00253-07

Jiang, S., He, Y., and Liu, S. (2005). SARS vaccine development. Emerg. Infect. Dis. 11, 1016–1020. doi:10.1284/jcm.2012.050219

Jiang, S., Hillier, C., and Du, L. (2020). Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 41, 355–359. doi:10.1016/j.ti.2020.03.007

Jin, L., Zeng, W., Zhang, F., Zhang, C., and Liang, W. (2017). Naringenin ameliorates acute inflammation by regulating intracellular cytokine degradation. J. Immunol. 199, 3466–3477. doi:10.4049/jimmunol.1602016

Kang, Y.-L., Chou, Y.-Y., Rothlauf, P. W., Liu, Z., Piccinotti, S., Soh, T. K., et al. (2020). Inhibition of PIKfyve kinase prevents infection by EBOV and SARS-CoV-2. bioRxiv doi:10.1101/2020.04.21.053058

Kazi, M. S., Saurabh, K., Rishi, P., and Rishi, E. (2013). Delayed onset chloroquine retinopathy presenting 10 years after long-term usage of chloroquine. Middle East Afr. J. Ophthalmol. 20, 89–91. doi:10.4103/0974-9233.106404

Kenney, D. L., and Benaroch, E. E. (2015). The autophagy-lysosomal pathway. Neurology 85, 634–645. doi:10.1212/wnl.000000000001860

Khan, N. (2020). Possible protective role of 17β estradiol against COVID-19. J. Allergy Infect. Dis. 1, 38–48. doi:10.4639/allergy.1.1010

Khan, N., Halcrow, P. W., Lakpa, K. L., Afgah, Z., Miller, N. M., Dowdy, S. F., et al. (2020). Two-pore channels regulate Tat endolysome escape and Tat-mediated HIV-1 LTR transactivation. FASEB J. 34, 4147–4162. doi:10.1096/fj.201902534r

Khan, N., Haughey, N. J., Nath, A., and Geiger, J. D. (2019a) Involvement of organelles and inter-organellar signaling in the pathogenesis of HIV-1 associated neurocognitive disorder and Alzheimer’s disease. Brain Res. 1722, 146389. doi:10.1016/j.brainsci.2019.146389

Khan, N., Lakpa, K. L., Halcrow, P. W., Afgah, Z., Miller, N. M., Geiger, J. D., et al. (2019b) BK channels regulate extracellular Tat-mediated HIV-1 LTR transactivation. Sci. Rep. 9, 12285. doi:10.1038/s41598-019-48777-y

Killian, M. (2012). Dual role of autophagy in HIV-1 replication and pathogenesis. AIDS Res. Ther. 9, 16. doi:10.1186/1742-6405-9-16

Kim, D., Min, J., Jang, M., Lee, J., Shin, Y., Park, C., et al. (2019). Natural bisbenzylisoquinoline alkaloids-tetrandanine, fanchinoline, and cepharnarine, inhibit human coronaviruses OC43 infection of MBC-5 human lung cells. Biomolecules 9, 696. doi:10.3390/biom9110696

Ko, D. C., Gordon, M. D., Jin, Y. J., and Scott, M. P. (2001). Dynamic movements of organelles containing niemann-pick C1 protein: NPC1 involvement in late endocytic events. MBoC 12, 601–614. doi:10.1091/mbo.12.3.601

Ko, M., Chang, S. Y., Byun, S. Y., Choi, I., d’Alexandry d’Oregianli, A.-L. P. H., Shum, D., et al. (2020). Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19. bioRxiv doi:10.1101/2020.02.25.965582

Kong, P. F., Rupasinghe, T. W., Simpson, J. A., Vodstrcil, L. A., Fairley, C. K., McConville, M. J., et al. (2017). Pharmacokinetics of a single 1g dose of β-estradiol against COVID-19. journal.pone.0174372. doi:10.1371/journal.pone.0174372

Kong, R., Xu, K., Zhou, T., Acharya, P., Lemmin, T., Liu, K., et al. (2016). Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science 352, 828–833. doi:10.1126/science.aee0474

Kuzniak, A., Benčina, M., Sväger, U., Jeras, M., Rozman, B., and Jerala, R. (2011). Mechanism of endosomal TLR inhibition by antimalarial drugs and dideminozidines. J. Immunol. 186, 4794–4804. doi:10.4049/jimmunol.1000702

Kwon, H. J., Abi Mosleh, L., Wang, M. L., Deissenhofer, J., Goldstein, J. L., Brown, M. S., et al. (2009). Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell 137, 1213–1224. doi:10.1016/j.cell.2009.03.049

Kwon, S. A., Kugemann, A., Carpenato, A., Böckmann, R. A., and Dietrich, P. (2018). Phosphatidylinositol-3,5-bisphosphate lipid-binding-induced
activation of the human two-pore channel 2. Cell. Mol. Life Sci. 75, 3803–3815. doi:10.1007/s00018-018-2829-5
Kyei, G. B., Dunkin, C., Davis, A. S., Roberts, E., Singh, S. B., Dong, C., et al. (2009). Autophagy pathway intersects with HIV-1 biosynthesis and regulates viral yields in macrophages. J. Cell Biol. 186, 255–268. doi:10.1083/jcb.200903070
Lagostena, L., Festa, M., Pusch, M., and Carpaneto, A. (2017). The human two-pore channel 2 is modulated by cytosolic and luminal calcium. Sci. Rep. 7, 43900. doi:10.1038/srep43900
Lange, Y., Ye, J., and Steck, T. L. (2012). Activation mobilizes the cholesterol in the late endosomes-lysosomes of niemann pick type C cells. PLoS One 7, e30051. doi:10.1371/journal.pone.0030051
Lee, J. S., and Shin, E.-C. (2020). The type I interferon response in COVID-19: implications for treatment. Nat. Rev. Immunol. 20, 585–586. doi:10.1038/s41577-020-00429-3
Lee, M. S., and Kim, Y.-J. (2007). Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu. Rev. Biochem. 76, 447–480. doi:10.1146/annurev.biochem.76.050605.122847
Letko, M., Marzi, A., and Munster, V. (2020). Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. FEBS Lett. 659, 3–12. doi:10.1016/j.febslet.2020.01.051
Li, C., Deng, Y.-Q., Wang, S., Ma, F., Aliyari, R., Huang, X.-Y., et al. (2017). 25-Hydroxycalcitriol activates AMPK through the grapefruit CYP3A4-dependent cholesterol production of 25-hydroxycholesterol. FEBS Lett. 590, 2056–2063. doi:10.1002/ﬂl3.16327
Liu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., et al. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origin and receptor binding. Lancet 395, 565–574. doi:10.1016/s0140-6736(20)30251-8
Luzio, J. P., Gray, S. R., and Bright, N. A. (2010). Endosome-lysosome fusion. Biochem. Soc. Trans. 38, 1413–1416. doi:10.1042/bst038i143
Luzio, J. P., Pryor, P. R., and Bright, N. A. (2007). Lysosomes: fusion and function. Nat. Rev. Mol. Cell Biol. 8, 622–632. doi:10.1038/nrm2217
Lyu, J., Yang, E. J., Head, S. A., Ai, N., Zhang, B., Wu, C., et al. (2017). Pharmacological blockade of cholesterol trafficking by cepharanthine in endothelial cells suppresses angiogenesis and tumor growth. Canc. Lett. 409, 91–103. doi:10.1016/j.canlet.2017.09.009
Maier, H., and Britton, P. (2012). Involvement of autophagy in coronavirus replication. Viruses 4, 3440–3451. doi:10.3390/v4121240
Marchant, J. S., and Patel, S. (2015). Two-pore channels at the intersection of endosomal membrane traffic. Biochem. Soc. Trans. 43, 434–441. doi:10.1042/bst20144033
Matsuda, K., Hattori, S., Komizu, Y., Kariya, R., Ueoka, R., and Okada, S. (2014). Cepharanthine inhibited HIV-1 cell-cell transmission and cell-free infection via modification of cell membrane fluidity. Bioorg. Med. Chem. Lett. 24, 2115–2117. doi:10.1016/j.bmcl.2014.03.041
McCaffrey, M. W., Bielli, A., Cantaluppo, G., Mora, S., Roberti, V., Santillo, M., et al. (2001). Rab4 affects both recyclying and degradative endosomal trafficking. FEBS Lett. 495, 21–30. doi:10.1016/s0014-5793(01)02539-6
Meutiawati, F., Bezemer, B., Strating, J. R. P. M., Overheul, G. J., Žaisnaitė, E., van Kuppeveld, F. J. M., et al. (2018). Posaconazole inhibits dengue virus replication by targeting oxysterol-binding protein. Antivir. Res. 157, 68–79. doi:10.1016/j.antiviral.2018.06.017
Millet, J. K., and Whittaker, G. R. (2014). Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc. Natl. Acad. Sci. U.S.A. 111, 15214–15219. doi:10.1073/pnas.1407087111
Mindell, J. A. (2012). Lysosomal acidification mechanisms. Annu. Rev. Physiol. 74, 69–86. doi:10.1146/annurev-physiol-012110-142317
Mingo, R. M., Simmons, J. A., Shoemaker, C. J., Nelson, E. A., Schornberg, K. L., D’Souza, R. S., et al. (2015). Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+Endolysosomes is a rate-deciding step. J. Virol. 89, 2931–2943. doi:10.1128/jvi.03398-14
Mullock, B. M., Bright, N. A., Fearon, C. W., Gray, S. R., and Luzio, J. (1998). Fusion of lysosomes with late endosomes produces a hybrid organelle of intermediate density and is NSF dependent. J. Cell Biol. 140, 591–601. doi:10.1083/jcb.140.3.591
Munz, C. (2012). Antigen processing for MHC class II presentation via autophagy. Front. Immunol. 3. doi:10.3389/fimmu.2012.00009
Nahmas, Y., Goldwasser, J., Casali, M., van Poll, D., Wakita, T., Chung, R. T., et al. (2008). Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. J. Cell Sci. 121, 447–448. doi:10.1242/jcs.04088
Nakanura, S., and Yoshimori, T. (2017). New insights into autophagosome-lysosome fusion. J. Cell Sci. 130, 1209–1216. doi:10.1242/jcs.196352
Offerhaus, J. A., Wilde, A. A. M., and Remme, C. A. (2020). Prophylactic (hydroxy)chloroquine in COVID-19: potential relevance for cardiac arrhythmia risk. Heart Rhythm 17, 1480–1486. doi:10.1016/j.hrthm.2020.07.001
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., et al. (2020). Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11, 1620. doi:10.1038/s41467-020-15562-9
Pälty, M., Reményi, A., and Korcsmáros, T. (2012). Endosomal crosstalk: meeting points for signaling pathways. Trends Cell Biol. 22, 447–456. doi:10.1016/j.tcb.2012.06.004
Pafumi, I., Festi, M., Papacci, F., Lagostena, L., Giunta, C., Gullà, V., et al. (2017). Naringenin impairs two-portal channel 2 activity and inhibits VEGF-induced angiogenesis. Sci. Rep. 7, 5211. doi:10.1038/s41598-017-04974-1
Pattingre, S., Tassa, A., Qu, X., Garuti, R., Liang, X. H., Mizushima, N., et al. (2005). Binding interaction of SARS coronavirus 3CLproprotease with vacuolar H+ATPase G1 subunit. J. Biol. Chem. 280, 3445–3448. doi:10.1074/jbc.M507987200
Pitkin, S. I., Funnell, T. M., Sitsapesan, M., Venturi, E., Rietdijk, K., Ruas, M., et al. (2010). TP2C is a novel NAADP-sensitive Ca2+-release channel, operating as a
Zheng, Y., Shang, J., Yang, Y., Liu, C., Wan, Y., Geng, Q., et al. (2018). Lysosomal proteases are a determinant of coronavirus tropism. J. Virol. 92, e01504–e01518. doi:10.1128/jvi.01504-18

Zhou, N., Pan, T., Zhang, J., Li, Q., Zhang, X., Bai, C., et al. (2016). Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J. Biol. Chem. 291, 9218–9232. doi:10.1074/jbc.m116.716100

Zhou, Y., Vedantham, P., Lu, K., Agudelo, J., Carrion, R., Jr., Nunneley, J. W., et al. (2015). Protease inhibitors targeting coronavirus and filovirus entry. Antivir. Res. 116, 76–84. doi:10.1016/j.antiviral.2015.01.011

Zhu, X., Yao, P., Liu, J., Guo, X., Jiang, C., and Tang, Y. (2020). Baicalein attenuates impairment of hepatic lysosomal acidification induced by high fat diet via maintaining V-ATPase assembly. Food Chem. Toxicol. 136, 110990. doi:10.1016/j.fct.2019.110990

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Khan, Chen and Geiger. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.